<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551212</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001HDE13</org_study_id>
    <secondary_id>2011-003118-17</secondary_id>
    <nct_id>NCT01551212</nct_id>
  </id_info>
  <brief_title>Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients</brief_title>
  <acronym>HEPHAISTOS</acronym>
  <official_title>A 12-month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate Efficacy/Safety and Evolution of Renal Function of Everolimus in Co-exposure With Tacrolimus in de Novo Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus
      versus a standard immunosuppressive regimen concerning kidney function in liver transplant
      recipients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2012</start_date>
  <completion_date type="Actual">August 8, 2017</completion_date>
  <primary_completion_date type="Actual">August 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Glomerular Filtration Rate (GFR)</measure>
    <time_frame>month 12</time_frame>
    <description>The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated GFR - PP Set</measure>
    <time_frame>month 12</time_frame>
    <description>This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HCV</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HCV Related Fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of de Novo HCC Malignancies</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of CMV Viral Infections.</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>EVR/TAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg</description>
    <arm_group_label>EVR/TAC</arm_group_label>
    <other_name>RAD001 / Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>capsule containing 0.5, 1.0, or 5.0mg</description>
    <arm_group_label>EVR/TAC</arm_group_label>
    <arm_group_label>TAC</arm_group_label>
    <other_name>Tacrolimus Hexal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator`s discretion, but may not have been eliminated sooner than 6 months post-transplantation.</description>
    <arm_group_label>EVR/TAC</arm_group_label>
    <arm_group_label>TAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Male or female recipients of a full-size liver allograft, aged 18 to 65 years.

        Exclusion criteria:

        Patients with thrombocytopenia (platelets &lt;50,000/mm³), with an absolute neutrophil count
        of &lt;1,000/mm³ or leucopenia (leucocytes &lt;2000/mm³), with anemia with Hb &lt; 6g/dl at time of
        randomization

        Patients with uncontrolled hypercholesterolemia (&gt;350mg/dL; &gt;9mmol/L) or
        hypertriglyceridemia (&gt;750 mg/dL; &gt;8.5 mmol/L) at time of randomization

        History of malignancy of any organ system within the past 5 years whether or not there is
        evidence of local recurrence or metastases, other than non-metastatic basal or squamous
        cell carcinoma of the skin or HCC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>August 2, 2018</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Renal function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 19, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT01551212/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT01551212/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 642 patients were screened for study eligibility at 15 study centers in Germany. 339 patients were randomized out of which 333 received study treatment and were included in the analyses.</recruitment_details>
      <pre_assignment_details>Patients were screened for eligibility prior to liver transplantation (LTx). The study treatment started after a run-in period that ended on the day of randomization, scheduled at Day 7-21 post-LTx. Patients may have been initiated on an optional induction therapy, MMF, TAC at investigators’ discretion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus/Tacrolimus</title>
          <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
        </group>
        <group group_id="P2">
          <title>Tacrolimus</title>
          <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Anylsis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Set (PP)</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Graft loss/Retransplantation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus/Tacrolimus</title>
          <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
        </group>
        <group group_id="B2">
          <title>Tacrolimus</title>
          <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="169"/>
            <count group_id="B2" value="164"/>
            <count group_id="B3" value="333"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full Analysis Set (FAS)</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.68" spread="9.38"/>
                    <measurement group_id="B2" value="53.46" spread="9.64"/>
                    <measurement group_id="B3" value="53.57" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Full Analysis Set (FAS)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Glomerular Filtration Rate (GFR)</title>
        <description>The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).</description>
        <time_frame>month 12</time_frame>
        <population>FAS (Full Analysis Set - All Randomized AND Treated Patients) with LOCF (last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (GFR)</title>
          <description>The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).</description>
          <population>FAS (Full Analysis Set - All Randomized AND Treated Patients) with LOCF (last observation carried forward)</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.46" spread="25.57"/>
                    <measurement group_id="O2" value="71.95" spread="27.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.097</p_value>
            <method>ANCOVA</method>
            <method_desc>factors: treatment, center, HCV-Class (positive, negative) and lab MELD (≤ 30 vs &gt; 30) covariate: baseline value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>8.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated GFR - PP Set</title>
        <description>This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.</description>
        <time_frame>month 12</time_frame>
        <population>Per Protocol Set (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated GFR - PP Set</title>
          <description>This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.</description>
          <population>Per Protocol Set (PP)</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.83" spread="25.19"/>
                    <measurement group_id="O2" value="70.65" spread="24.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0085</p_value>
            <method>ANCOVA</method>
            <method_desc>factors: treatment, center, HCV-Class (positive, negative) and lab MELD (≤ 30 vs &gt; 30) covariate: baseline value</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.06</ci_lower_limit>
            <ci_upper_limit>13.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death</title>
        <description>Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12</description>
        <time_frame>12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death</title>
          <description>Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12</description>
          <population>FAS</population>
          <units>Percent of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HCV</title>
        <description>Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest</description>
        <time_frame>12 months</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HCV</title>
          <description>Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of HCV Related Fibrosis</title>
        <description>Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest</description>
        <time_frame>12 months</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HCV Related Fibrosis</title>
          <description>Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of de Novo HCC Malignancies</title>
        <description>Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest</description>
        <time_frame>12 months</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of de Novo HCC Malignancies</title>
          <description>Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of CMV Viral Infections.</title>
        <description>Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.</description>
        <time_frame>12 months</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus/Tacrolimus</title>
            <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
          </group>
          <group group_id="O2">
            <title>Tacrolimus</title>
            <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of CMV Viral Infections.</title>
          <description>Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.</description>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No CMV viral infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asymptomatic</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Everolimus/Tacrolimus</title>
          <description>Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: &lt; 5 ng/mL)</description>
        </group>
        <group group_id="E2">
          <title>Tacrolimus</title>
          <description>Tacrolimus (C0-h: 6-10 ng/ml)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BONE MARROW TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>EVANS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPOCHROMIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TOXIC NODULAR GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MYDRIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INCARCERATED INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INCARCERATED UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INTESTINAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MESENTERIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MESENTERIC VENOUS OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SWOLLEN TONGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INCARCERATED HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN DYSFUNCTION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SURGICAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILIARY ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILIARY TRACT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATITIS TOXIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>NON-ALCOHOLIC STEATOHEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VANISHING BILE DUCT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>LIVER TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ATYPICAL PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILIARY ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILIARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS VIRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ENTERITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>EPIDIDYMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>EPSTEIN-BARR VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS CLOSTRIDIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS CRYPTOSPORIDIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS ROTAVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HUMAN HERPESVIRUS 6 INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INFECTED SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LIVER ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PHARYNGEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SCARLET FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TRANSPLANT ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BILIARY ANASTOMOSIS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>COMPLICATIONS OF TRANSPLANTED LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GRAFT LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INCARCERATED INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL BILE LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TRANSPLANT FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>WEANING FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHEST X-RAY ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GLUTAMATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ARTERY FLOW DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS HYPERCHLORAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DIABETIC COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERINSULINAEMIC HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>OSTEOCHONDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CHRONIC MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LACUNAR STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PARAPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ALBUMINURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>IGA NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DIABETIC VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INFERIOR VENA CAVA STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INTERNAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LYMPHATIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>POOR PERIPHERAL CIRCULATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="164"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="164"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

